Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Dexedrine Spansule. Every FDA application for this active ingredient: 1 branded and 39 generic.
As of Nov 14, 2026, FDA lists 40 applications for Dextroamphetamine Sulfate (sold as Dexedrine Spansule), first approved Aug 2, 1976, with 0 new uses approved and 0 published complete response letters.
First approved: Aug 2, 1976
Applications: 40
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $9.8M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Dextroamphetamine Sulfate
Part D
$5.0M
+7%
9,537
Dextroamphetamine Sulfate ER
Part D
$4.4M
-5%
5,706
Zenzedi
Part D
$221K
-21%
89
Dexedrine
Part D
$83K
-84%
13
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
DEXTROAMPHETAMINE 10 MG TAB: $0.382 per unitGeneric · -31% in a year
DEXTROAMPHETAMINE 15 MG TAB: $5.46 per unitGeneric · +2% in a year
DEXTROAMPHETAMINE 2.5 MG TAB: $3.93 per unitGeneric · new this year
DEXTROAMPHETAMINE 20 MG TAB: $5.33 per unitGeneric · +8% in a year
DEXTROAMPHETAMINE 30 MG TAB: $5.48 per unitGeneric · +9% in a year
DEXTROAMPHETAMINE 5 MG TAB: $0.411 per unitGeneric · -26% in a year
DEXTROAMPHETAMINE 5 MG/5 ML: $1.15 per MLGeneric · -6% in a year
DEXTROAMPHETAMINE 7.5 MG TAB: $5.83 per unitGeneric · new this year
DEXTROAMPHETAMINE ER 10 MG CAP: $1.04 per unitGeneric · -1% in a year
DEXTROAMPHETAMINE ER 15 MG CAP: $1.33 per unitGeneric · -5% in a year
DEXTROAMPHETAMINE ER 5 MG CAP: $1.29 per unitGeneric · +25% in a year
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Glaxosmithkline
Impax Labs Inc
Strides Pharma Intl
Teva
Sandoz